162 related articles for article (PubMed ID: 37418029)
21. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
[TBL] [Abstract][Full Text] [Related]
22. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells SA; Pacini F; Robinson BG; Santoro M
J Clin Endocrinol Metab; 2013 Aug; 98(8):3149-64. PubMed ID: 23744408
[TBL] [Abstract][Full Text] [Related]
23. Hereditary medullary thyroid carcinoma syndromes: experience from western India.
Diwaker C; Sarathi V; Jaiswal SK; Shah R; Deshmukh A; Thomas AE; Prakash G; Malhotra G; Patil V; Lila A; Shah N; Bandgar T
Fam Cancer; 2021 Jul; 20(3):241-251. PubMed ID: 33392850
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
25. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.
Peppa M; Boutati E; Kamakari S; Pikounis V; Peros G; Panayiotides IG; Economopoulos T; Raptis SA; Hadjidakis D
Eur J Endocrinol; 2008 Dec; 159(6):767-71. PubMed ID: 18805915
[TBL] [Abstract][Full Text] [Related]
26. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
27. The association between Hirschsprung's disease and multiple endocrine neoplasia type 2a: a systematic review.
Coyle D; Friedmacher F; Puri P
Pediatr Surg Int; 2014 Aug; 30(8):751-6. PubMed ID: 24972642
[TBL] [Abstract][Full Text] [Related]
28. RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family.
Quedas EP; Longuini VC; Sekiya T; Coutinho FL; Toledo SP; Tannuri U; Toledo RA
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):57-61. PubMed ID: 22584707
[TBL] [Abstract][Full Text] [Related]
29. RET codon 618 mutations in Saudi families with multiple endocrine neoplasia Type 2A and familial medullary thyroid carcinoma.
Qari F
Ann Saudi Med; 2013; 33(2):155-8. PubMed ID: 23563004
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and genetic analysis of seven Chinese pedigrees affected with multiple endocrine neoplasia type 2A with cutaneous lichen amyloidosis].
Fang X; Wang H; Dong F; Lian B; Li F; Jin H; Yu Y; Zhang N; Qi X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 Sep; 39(9):938-943. PubMed ID: 36082561
[TBL] [Abstract][Full Text] [Related]
31. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
32. Current understanding and management of medullary thyroid cancer.
Roy M; Chen H; Sippel RS
Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
[TBL] [Abstract][Full Text] [Related]
33. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene.
Decker RA; Peacock ML
J Pediatr Surg; 1998 Feb; 33(2):207-14. PubMed ID: 9498388
[TBL] [Abstract][Full Text] [Related]
34. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
Chang CF; Yang WS; Su YN; Wu IL; Chang TC
J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
[TBL] [Abstract][Full Text] [Related]
35. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel RF; van Amstel HK; Lips CJ; Nishisho I; Takai SI; Marsh DJ; Robinson BG; Frank-Raue K; Raue F; Xue F; Noll WW; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy GN; Mulligan LM
JAMA; 1996 Nov; 276(19):1575-9. PubMed ID: 8918855
[TBL] [Abstract][Full Text] [Related]
36. RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest.
Vaclavikova E; Dvorakova S; Sykorova V; Bilek R; Dvorakova K; Vlcek P; Skaba R; Zelinka T; Bendlova B
Endocrine; 2009 Dec; 36(3):419-24. PubMed ID: 19826964
[TBL] [Abstract][Full Text] [Related]
37. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
38. A MEN2A family with two asymptomatic carriers affected by unilateral renal agenesis.
Hibi Y; Ohye T; Ogawa K; Shimizu Y; Shibata M; Kagawa C; Mizuno Y; Kurahashi H; Iwase K
Endocr J; 2014; 61(1):19-23. PubMed ID: 24152999
[TBL] [Abstract][Full Text] [Related]
39. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].
Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R
Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805
[TBL] [Abstract][Full Text] [Related]
40. Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families.
Wang YP; Li FP; Wang HH; Fang XD; Zhu ZS; Chen YL; Qi XP
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):339-347. PubMed ID: 34445950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
